Stock comparison
Enovis
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ENOV
Enovis
Market cap
$1.47B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.4B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ENOV | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 20F | 65C | GMAB |
| Benjamin Graham | 24F | 64C | GMAB |
| Philip Fisher | 34F | 48D | GMAB |
| Peter Lynch | 30F | 25F | ENOV |
| Joel Greenblatt | 0F | 76B | GMAB |
| Charlie Munger | 29F | 68C | GMAB |
| Terry Smith | 24F | 71C | GMAB |
Side-by-side metrics
| Metric | ENOV | GMAB |
|---|---|---|
| Market cap | $1.47B | $16.4B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | - | 12.0x |
| ROIC (TTM) | 1.87% | 43.78% |
| Gross margin | 56.81% | 93.88% |
| Net margin | -49.91% | 18.23% |
| Revenue CAGR 5y | 12.05% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ENOV leads on
- Revenue CAGR 5y12.05%vs -18.45%+165%
- P/E (TTM)-vs 6.2x+120%
- EV/EBIT-vs 12.0x+108%
GMAB leads on
- Net margin18.23%vs -49.91%+137%
- ROIC (TTM)43.78%vs 1.87%+96%
- Debt / Equity0.1xvs 1.0x+92%
- Market cap$16.4Bvs $1.47B+91%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.